Eloxx Pharmaceuticals Inc at Barclays Global Healthcare Conference Transcript
Hello, everyone. Welcome to the final day of the Barclays Global Healthcare Conference. I'm Greg Harrison, an associate on Geoff Meacham's team. And today, we're lucky enough to have Eloxx Pharmaceuticals and Robert Ward, Chairman and CEO, with us today. Robert?
Thank you, [Greg], and we appreciate being included in the Barclay's Global Health Conference this year.
During the course of my presentation today, I'll be making forward-looking statements, and so I'd ask you that you refer to our most recent filings with the SEC. And we did record our earnings call just this past week.
So we're very excited to have announced that Dr. Susan Schneider has joined the company now to lead our ophthalmology program. For this year at Eloxx, with our cystic fibrosis program poised to achieve topline data in Phase II, our cystinosis program also on track for Phase II readout, our expansion to inherited retinal
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |